Article Information
History
- May 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Rebecca H. Haberman, MD, MSCI1,+,
- Ramin Sedaghat Herati, MD1,+,
- David Simon, MD2,+,
- Marie Samanovic, PhD1,+,
- Rebecca B. Blank, MD, PhD1,
- Michael Tuen, PhD1,
- Sergei B. Koralov, PhD1,
- Raja Atreya, MD2,
- Koray Tascilar, MD2,
- Joseph R. Allen1,
- Rochelle Castillo, MD1,
- Amber R. Cornelius1,
- Paula Rackoff, MD1,
- Gary Solomon, MD1,
- Samrachana Adhikari, PhD1,
- Natalie Azar, MD1,
- Pamela Rosenthal, MD1,
- Peter Izmirly, MD1,
- Jonathan Samuels, MD1,
- Brian Golden, MD1,
- Soumya Reddy, MD1,
- Markus Neurath, MD2,
- Steven B. Abramson, MD1,
- Georg Schett, MD, PhD2,*,
- Mark J. Mulligan, MD1,* and
- Jose U. Scher, MD1,*
- 1New York University Langone Health, New York, NY
- 2FAU Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany
- ↵*To whom correspondence should be addressed: J.U.S. jose.scher{at}nyulangone.org; G.S. Georg.Schett{at}uk-erlangen.de; M.M. mark.mulligan{at}nyulangone.org (equal contribution)
↵+ R. Haberman, R. Herati, D. Simon and M. Samanovic contributed equally to this paper.
Posted May 12, 2021.
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
